1. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.
2. Bristol-Myers Squibb Company. Product information: MAXIPIME® IV, IM injection, cefepime HCl IV, IM injection. Princeton: Bristol-Myers Squibb Company. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050679s032lbl.pdf (2009). Accessed 18 Jan 2011.
3. Whitby DH, Johns TE. Drug-induced hematologic disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy. A pathophysiologic approach. 7th ed. New York: McGraw-Hill Companies, Inc.; 2008. pp. 1701–1714. (ISBN 978-0-07-147899-1).
4. Gralnick HR, Mcginniss M, Halterman R. Thrombocytopenia with sodium cephalothin therapy. Ann Intern Med. 1972;77(3):401–4.
5. Lown JA, Barr AL. Immune thrombocytopenia induced by cephalosporins specific for thiomethyltetrazole side chain. J Clin Pathol. 1987;40:700–1.